Skip to main content Accessibility help
×
Home

Cetuximab in the management of nasopharyngeal carcinoma – a narrative review

  • M S Iqbal (a1), D Wilkinson (a2), A Tin (a2), P Bossi (a3), L Gradwell-Nelson (a4), J Kovarik (a1), J O'Hara (a4) and C Kelly (a1)...

Abstract

Background

Concurrent chemotherapy with radiotherapy is the standard treatment for locoregionally advanced nasopharyngeal cancer. Cetuximab can be used in the treatment of head and neck squamous cell carcinoma. However, the randomised studies that led to approval for its use in this setting excluded nasopharyngeal cancer. In the context of limited data for the use of cetuximab in nasopharyngeal cancer in the medical literature, this review aimed to summarise the current evidence for its use in both primary and recurrent or metastatic disease.

Method

A literature search was performed using the keywords ‘nasopharyngeal neoplasm’, ‘cetuximab’ and ‘Erbitux’.

Results

Twenty studies were included. There were no randomised phase III trials, but there were nine phase II trials. The use of cetuximab in the treatment of nasopharyngeal carcinoma has been tested in various settings, including in combination with induction chemotherapy and concurrent chemoradiotherapy, and in the palliative setting.

Conclusion

There is no evidence of benefit from the addition of cetuximab to standard management protocols, and there is some evidence of increased toxicity. There is more promise for its use in metastatic or locally recurrent settings. This review draws together the existing evidence and could provide a focus for future studies.

Copyright

Corresponding author

Author for correspondence: Dr Muhammad Shahid Iqbal, Northern Centre for Cancer Care, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne NE7 7DN, UK E-mail: shahid.iqbal@nhs.net

Footnotes

Hide All

Dr M S Iqbal takes responsibility for the integrity of the content of the paper

Footnotes

References

Hide All
1Lee, AW, Lin, JC, Ng, WT. Current management of nasopharyngeal cancer. Semin Radiat Oncol 2012;22:233–44
2You, R, Cao, YS, Huang, PY, Chen, L, Yang, Q, Liu, YP et al. The changing therapeutic role of chemo-radiotherapy for loco-regionally advanced nasopharyngeal carcinoma from two/three-dimensional radiotherapy to intensity-modulated radiotherapy: a network meta-analysis. Theranostics 2017;7:4825–35
3Al-Sarraf, M, LeBlanc, M, Giri, PG, Fu, KK, Cooper, J, Vuong, T et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 1998;16:1310–17
4Putti, TC, To, KF, Hsu, HC, Chan, AT, Lai, GM, Tse, G et al. Expression of epidermal growth factor receptor in head and neck cancers correlates with clinical progression: a multicentre immunohistochemical study in the Asia-Pacific region. Histopathology 2002;41:144–51
5Ma, BB, Poon, TC, To, KF, Zee, B, Mo, FK, Chan, CM et al. Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma--a prospective study. Head Neck 2003;25:864–72
6Chua, DT, Nicholls, JM, Sham, JS, Au, GK. Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys 2004;59:1120
7Bonner, JA, Harari, PM, Giralt, J, Cohen, RB, Jones, CU, Sur, RK et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010;11:21–8
8Vermorken, JB, Mesia, R, Rivera, F, Remenar, E, Kawecki, A, Rottey, S et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359:1116–27
9Feng, HX, Guo, SP, Li, GR, Zhong, WH, Chen, L, Huang, LR et al. Toxicity of concurrent chemoradiotherapy with cetuximab for locoregionally advanced nasopharyngeal carcinoma. Med Oncol 2014;31:170
10Zhang, X, Du, L, Zhao, F, Wang, Q, Yang, S, Ma, L. A phase II clinical trial of concurrent helical tomotherapy plus cetuximab followed by adjuvant chemotherapy with cisplatin and docetaxel for locally advanced nasopharyngeal carcinoma. Int J Biol Sci 2016;12:446–53
11Chen, C, Zhao, C, Gao, L, Lang, J, Pan, J, Hu, C et al. Long-term result of a multicenter clinical study of cetuximab combined with intensity modulated radiotherapy (IMRT) plus concurrent chemotherapy in locoregionally advanced nasopharyngeal carcinoma (NPC). J Clin Oncol 2015;33(15 suppl):e17020
12Wu, LR, Zhu, HF, Xu, J, Jiang, XS, Yin, L, Jiang, N et al. Effectiveness of cetuximab in combination with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a 1:2 propensity score-matched analysis. J Cancer 2018;9:1642–51
13Li, Y, Chen, QY, Tang, LQ, Liu, LT, Guo, SS, Guo, L et al. Concurrent chemoradiotherapy with or without cetuximab for stage II to IVb nasopharyngeal carcinoma: a case-control study. BMC Cancer 2017;17:567
14He, X, Xu, J, Guo, W, Jiang, X, Wang, X, Zong, D. Cetuximab in combination with chemoradiation after induction chemotherapy of locoregionally advanced nasopharyngeal carcinoma: preliminary results. Future Oncol 2013;9:1459–67
15Ma, BB, Kam, MK, Leung, SF, Hui, EP, King, AD, Chan, SL et al. A phase II study of concurrent cetuximab-cisplatin and intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma. Ann Oncol 2012;23:1287–92
16Xia, WX, Liang, H, Lv, X, Wang, L, Qian, CN, Ye, YF et al. Combining cetuximab with chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma: a propensity score analysis. Oral Oncol 2017;67:167–74
17You, R, Hua, YJ, Liu, YP, Yang, Q, Zhang, YN, Li, JB et al. Concurrent chemoradiotherapy with or without anti-EGFR-targeted treatment for stage II-IVb nasopharyngeal carcinoma: retrospective analysis with a large cohort and long follow-up. Theranostics 2017;7:2314–24
18Zhu, G, Liu, Y, Guan, X, Hu, C, Li, F. Induction chemotherapy followed by concomitant chemoradiation versus cetuximab with radiation in locally-advanced nasopharyngeal carcinoma: initial results of a randomized phase 2 study. Int J Radiat Oncol Biol Phys 2013;87:S193
19Wu, X, Huang, J, Liu, L, Li, H, Li, P, Zhang, J et al. Cetuximab concurrent with IMRT versus cisplatin concurrent with IMRT in locally advanced nasopharyngeal carcinoma: a retrospective matched case-control study. Medicine (Baltimore) 2016;95:e4926
20Xu, T, Liu, Y, Dou, S, Li, F, Guan, X, Zhu, G. Weekly cetuximab concurrent with IMRT aggravated radiation-induced oral mucositis in locally advanced nasopharyngeal carcinoma: results of a randomized phase II study. Oral Oncol 2015;51:875–9
21Niu, X, Hu, C, Kong, L. Experience with combination of cetuximab plus intensity-modulated radiotherapy with or without chemotherapy for locoregionally advanced nasopharyngeal carcinoma. J Cancer Res Clin Oncol 2013;139:1063–71
22Lin, PJ, Wang, WY, Liu, YC, Lin, JC. Treatment outcome of induction bio-chemotherapy followed by IMRT in advanced NPC patients. Radiother Oncol 2016;119(suppl 1):S508
23Peng, H, Tang, LL, Liu, X, Chen, L, Li, WF, Mao, YP et al. Anti-EGFR targeted therapy delivered before versus during radiotherapy in locoregionally advanced nasopharyngeal carcinoma: a big-data, intelligence platform-based analysis. BMC Cancer 2018;18:323
24Ng, WT, Ngan, RKC, Kwong, DLW, Tung, SY, Yuen, KT, Kam, MKM et al. Prospective, multicenter, phase 2 trial of induction chemotherapy followed by bio-chemoradiotherapy for locally advanced recurrent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2018;100:630–8
25Chan, AT, Hsu, MM, Goh, BC, Hui, EP, Liu, TW, Millward, MJ et al. Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J Clin Oncol 2005;23:3568–76
26Kerboua, E, Tahrat, A, Bouzid, K. A open label phase II trial of cetuximab plus cisplatin in patients with recurrent or metastatic undifferentiated carcinoma of nasopharyngeal type: results after three years. J Clin Oncol 2015;33:e17021
27Lin, T, Zhang, M, Huang, H, Li, X, Huang, Y, Chen, C et al. Prospective study of cetuximab with cisplatin plus docetaxel followed by concurrent radiotherapy plus cetuximab and cisplatin in patients with chemotherapy-naive metastatic nasopharyngeal carcinoma. Ann Oncol 2016;27(suppl 6):974
28Xu, T, Ou, X, Shen, C, Hu, C. Cetuximab in combination with chemoradiotherapy in the treatment of recurrent and/or metastatic nasopharyngeal carcinoma. Anticancer Drugs 2016;27:6670
29Blanchard, P, Lee, A, Marguet, S, Leclercq, J, Ng, WT, Ma, J et al. Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. Lancet Oncol 2015;16:645–55
30Ribassin-Majed, L, Marguet, S, Lee, AWM, Ng, WT, Ma, J, Chan, ATC et al. What is the best treatment of locally advanced nasopharyngeal carcinoma? An individual patient data network meta-analysis. J Clin Oncol 2017;35:498505
31Specenier, PM, Remenar, E, Buter, J, Schrijvers, DL, Bergamini, C, Licitra, LF et al. TPF plus cetuximab induction chemotherapy followed by biochemoradiation with weekly cetuximab plus weekly cisplatin or carboplatin: a randomized phase II EORTC trial. Ann Oncol 2017;28:2219–24
32Licitra, L, Bossi, P, Locati, LD, Bergamini, C. Is restoring platinum sensitivity the best goal for cetuximab in recurrent/metastatic nasopharyngeal cancer? J Clin Oncol 2005;23:7757–8

Keywords

Cetuximab in the management of nasopharyngeal carcinoma – a narrative review

  • M S Iqbal (a1), D Wilkinson (a2), A Tin (a2), P Bossi (a3), L Gradwell-Nelson (a4), J Kovarik (a1), J O'Hara (a4) and C Kelly (a1)...

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed